Trial reportPediatric nephrology (Berlin, Germany)2005
Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome.
Trial report in Pediatric nephrology (Berlin, Germany), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 4 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- Pediatric idiopathic steroid-sensitive nephrotic syndrome: diagnosis and therapy -short version of the updated German best practice guideline (S2e) - AWMF register no. 166-001, 6/2020.Pediatric nephrology (Berlin, Germany) · 2021Guideline
- Systematic Review and Meta-Analysis of Rituximab for Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome in Children.Frontiers in pediatrics · 2021Pooled it
- Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy.Clinical and experimental nephrology · 2015Guideline
- Immunosuppressive treatment for focal segmental glomerulosclerosis in adults.The Cochrane database of systematic reviews · 2008Pooled it
- Trial
- Efficacy of higher-dose levamisole in maintaining remission in steroid-dependant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2017Trial
- Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome.Journal of the American Society of Nephrology : JASN · 2013Trial
- Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis.Pediatric nephrology (Berlin, Germany) · 2013Trial
- Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial.Pediatric nephrology (Berlin, Germany) · 2012Trial
- Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2010Trial
- Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.British journal of clinical pharmacology · 2010Trial
- Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2008Trial
- Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2007Trial
- A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2007Trial
- Effective calcineurin inhibitor treatment in adult-onset steroid-resistant nephrotic syndrome with a novel splice donor site variant of TRPC6: a case report.CEN case reports · 2025Article
- Efficacy analysis of rituximab in treating patients with primary membranous nephropathy dependent on calcineurin inhibitors.Frontiers in immunology · 2024Article
- Article
- Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy.Scientific reports · 2021Observational
- Steroid Sensitive Nephrotic Syndrome: Revised Guidelines.Indian pediatrics · 2021Article
- Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Attempts to minimize the effects of prolonged steroid use in steroid-dependent nephrotic syndrome (SDNS) and the need to overcome steroid resistance (SRNS) justifies immunosuppressant therapy. We report our experience in a cohort of patients with SD/SRNS during the administration of mycophenolate mofetil (MMF) in a prospective protocol initiated in January 2001. Twenty-six children with idiopathic nephrotic syndrome were included (21 steroid dependent and 5 steroid resistant), whose response did not change after sequential treatment with cyclophosphamide (CPM) and cyclosporine (CsA). Histopathologic patterns were: 11 minimal change disease (MCD), 1 diffuse mesangial proliferation (DMP), 13 focal segmental glomerulosclerosis (FSGS) and membranous 1 glomerulonephritis (MGN). The median age of onset of NS was 2.8 years (range 1.2-12.5), and treatment with MMF was performed at a median age of 11.4 years (range 5-17) with an initial dose of 600 mg/m(2)/12 h, adjusted to maintain levels of mycophenolic acid (MPA) at 2.5-5 mcg/ml. The planned duration of study to assess treatment efficacy was 6 months. The mean MMF dose required was 624 (SD=136) mg/m(2)/12 h (range 415-970), which maintained mean C(0)-MPA levels of 2.9 (SD=1.17) mcg/ml (range 1.2-5.9 mcg/ml). In the five patients with SRNS, only one achieved complete remission. In the patients with SDNS, steroid sparing was achieved in 15 and 9 remained in remission on MMF monotherapy. Withdrawal of MMF resulted in immediate relapse in 47%. In our study, MMF was a useful immunosuppressant due to its fewer undesirable effects and similar efficacy to other drugs used. It appears effective for the maintenance of remission in SDNS patients, with a response similar to that of CsA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.